PharmaEssentia revenue and financials
$1,175.00Change from previous close: 0.00%
In the fiscal year ended December 2025, PharmaEssentia reported revenue of $15.63B (+60.61% year over year). Net income was $5.05B, a net margin of 32.3%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +60.61%
- 2025 vs 2024
- Net income growth
- +70.13%
- 2025 vs 2024
- Net margin
- 32.3%
- 2024: 30.5%
Financial data
Amounts in millions of TWD; per-share values in TWD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 37,411 | 31,062 | 27,269 | 15,333 | — |
| Current assets | 29,044 | 25,417 | 22,896 | 13,375 | — |
| Cash and equivalents | 22,693 | 21,051 | 19,666 | 10,304 | — |
| Short-term investments | 24.1 | 23.6 | 22.2 | 976 | — |
| Inventory | 1,298 | 1,277 | 1,459 | 1,102 | — |
| Net property, plant and equipment | 5,290 | 3,560 | 2,836 | 1,045 | — |
| Long-term investments | 50.6 | 0.0 | — | — | — |
| Current liabilities | 4,681 | 2,557 | 2,152 | 2,550 | — |
| Accounts payable | 157 | 126 | 129 | 231 | — |
| Long-term debt | 44.8 | 50.8 | 62.7 | 75.0 | — |
| Total debt | 856 | 965 | 1,200 | 1,569 | — |
| Total liabilities | 5,436 | 3,593 | 3,321 | 3,191 | — |
| Total equity (incl. minority) | 31,975 | 27,469 | 23,948 | 12,141 | — |
| Retained earnings | 6,947 | 2,974 | -631 | -4,186 | — |